ClinicalTrials.gg
CompletedNCT04676191Updated Jan 25, 2022

Validation of a Contactless Vital Signs Measurement Sensor

An interventional study of Sleepiz One+ and Polysomnography in Sleep Apnea, sponsored by Sleepiz AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Sleepiz AG · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Sleep Apnea Syndromes with a site in Switzerland — 7 open to participants now, 9 under way, none of them phase 3. Sleep Apnea Syndromes · Switzerland.

Enrollment
12th of 27
64 · median 60
Started
2020
with 2 others
No phase
21 of 37
5 open now
Registered
25th of 37
by date
Lead sponsor
4 of 37
Sleepiz AG

Among the 37 studies in Sleep Apnea Syndromes with a site in Switzerland, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 with no phase, and was the 25th registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

7 of the 37 studies in Sleep Apnea Syndromes with a site in Switzerland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Sleep Apnea Syndromes with a site in Switzerland, or all of them as a file.
02

Study summary

The primary aim of this study is to validate the performance of Sleepiz One+ for the measurement of vital physiological parameters in adult population, against a laboratory-based polysomnography. Additionally, the investigators will evaluate Sleepiz One+ ability to identify patients with a high risk of suffering from a sleep-related breathing disorder based on apnea-hypopnea index estimation. Participants will undergo measurement with Sleepiz One+ and a polysomnography device while resting in bed for 20 min as well as during sleep for the duration of the following night.

03

Conditions studied

  • Sleep Apnea

Keywords

  • respiration
  • sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18years
  • Ability and consent to undergo electrophysiological routine assessment
  • as documented by signature
  • Patients diagnosed or suspected to suffer from sleep apnea or any other sleep related disorder or patients suffering from chronic cardiac, respiratory or neuromuscular disorders
  • Ambulatory or stationary patients of Klinik Lengg

Exclusion criteria

Exclusion Criteria:

  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Cardiac pacemaker or another implanted electrical device
  • Women who are pregnant
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, delirium etc. of the participant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Patients with sleep disorders, cardiorespiratory or neuromuscular disorders

    Device: Sleepiz One+ · Device: Polysomnography

Interventions

  • DeviceSleepiz One+

    Simultaneous sleep study with polysomnography and Sleepiz One+

  • DevicePolysomnography

    Simultaneous sleep study with polysomnography and Sleepiz One+

06

What researchers measure

Primary outcomes

  1. Respiration rate measurement accuracy agreement

    Time frame: 60 seconds

Secondary outcomes

  1. Binary classification of sleep apnea severity based on the AHI > 15 of Sleepiz One+ compared to results of Domino software and data manually scored by sleep technician

    Time frame: 1 Night

  2. Instantaneous respiration rate agreement between Sleepiz One+ and nasal cannula

    Time frame: 60 seconds

  3. Average respiration rate agreement between Sleepiz One+ and thoracic respiratory effort belt

    Time frame: 1 Night

  4. Average respiration rate agreement between Sleepiz One+ and nasal cannula

    Time frame: 1 Night

  5. Sleep/wake classification agreement between Sleepiz One+ compared to polysomnography (PSG) data manually scored by sleep technician

    Time frame: 60 seconds

07

Study locations

1 site
  • Klinik Lengg AG
    Zurich, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2021, 4 months.

Of 69 industry-sponsored interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 19, 2020
StartActual
Sep 10, 2020
Primary completionActual
Feb 2, 2021
CompletionActual
Jan 12, 2022
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04676191
Lead sponsor
Sleepiz AG
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Sep 10, 2020
Primary completion
Feb 2, 2021
Completion
Jan 12, 2022
Last update
Jan 25, 2022

Study contacts

Bartosz Bujan, Dr. med.
principal investigator · Klinik Lengg, Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion